Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
Exelixis Inc. is heartened by broader inclusion in National Comprehensive Cancer Network (NCCN) clinical practice guidelines for Cabometyx (cabozantinib) across risk groups in first-line kidney cancer, though the tyrosine kinase inhibitor doesn't have as high of a rating as Bristol-Myers Squibb Co.'s immunotherapy combination of Yervoy and Opdivo.
Cabozantinib is an oral drug that works on a number of targets, including VEGFR2, MET and RET. The drug was...
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.
